Need immediate assistance? Call 1-518-730-0559 (Us-Canada Toll Free) or Contact Us

 

Global Market Study on Malignant Mesothelioma: Cisplatin and Combination Segment Projected to be the Second Most Lucrative Segment by Drug Type

Table of Content

1. Executive Summary
   1.1. Market Overview
   1.2. Market Analysis
   1.3. PMR Analysis and Recommendations
   1.4. Wheel of Fortune

2. Market Introduction
   2.1. Market Definition
   2.2. Market Taxonomy

3. Malignant Mesothelioma Market Opportunity Analysis
   3.1. Macro-Economic Factors
   3.2. Demand and Supply side Driver
   3.3. Global Trend
   3.4. Pipeline Snapshot
   3.5. Medicines in Development for Malignant Mesothelioma, 2016
   3.6. Asbestos Production By Country
   3.7. Asbestos Consumption By Country
   3.8. Epidemiology Data

4. North America Malignant Mesothelioma Market Analysis 2012–2016 and Forecast 2017–2025
   4.1. Introduction
   4.2. Key Regulations
   4.3. Regional Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Trends
   4.4. Historical Market Size (US$ Mn) Analysis By Country, 2012–2016
        4.4.1. U.S.
        4.4.2. Canada
   4.5. Market Size (US$ Mn) Forecast By Country, 2017–2025
        4.5.1. U.S.
        4.5.2. Canada
   4.6. Historical Market Size (US$ Mn) Analysis By Drug Class, 2012–2016
        4.6.1. Premetrexed and combination
        4.6.2. Cisplatin and combination
        4.6.3. Carboplatin and combination
        4.6.4. Gemcitabine and combination
        4.6.5. Vinorelbine and combination
        4.6.6. Others combinations
   4.7. Market Size (US$ Mn) Forecast By Drug Class, 2017–2025
        4.7.1. Premetrexed and combination
        4.7.2. Cisplatin and combination
        4.7.3. Carboplatin and combination
        4.7.4. Gemcitabine and combination
        4.7.5. Vinorelbine and combination
        4.7.6. Others combinations
   4.8. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2012–2016
        4.8.1. Oral
        4.8.2. Parenteral
   4.9. Market Size (US$ Mn) Forecast By Route of Administration, 2017–2025
        4.9.1. Oral
        4.9.2. Parenteral
   4.10. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2012–2016
        4.10.1. Hospital Pharmacies
        4.10.2. Retail Pharmacies
        4.10.3. Oncology Centers
   4.11. Market Size (US$ Mn) Forecast By Distribution Channel, 2017–2025
        4.11.1. Hospital Pharmacies
        4.11.2. Retail Pharmacies
        4.11.3. Oncology Centers
   4.12. Drivers and Restraints: Impact Analysis
   4.13. Market Attractiveness Analysis
        4.13.1. By Country
        4.13.2. By Drug Class
        4.13.3. By Route of Administration
        4.13.4. By Distribution Channel

5. Latin America Malignant Mesothelioma Market Analysis 2012–2016 and Forecast 2017–2025
   5.1. Introduction
   5.2. Key Regulations
   5.3. Regional Market Dynamics
        5.3.1. Drivers
        5.3.2. Restraints
   5.4. Historical Market Size (US$ Mn) Analysis By Country, 2012–2016
        5.4.1. Brazil
        5.4.2. Mexico
        5.4.3. Rest of Latin America
   5.5. Market Size (US$ Mn) Forecast By Country, 2017–2025
        5.5.1. Brazil
        5.5.2. Mexico
        5.5.3. Rest of Latin America
   5.6. Historical Market Size (US$ Mn) Analysis By Drug Class, 2012–2016
        5.6.1. Premetrexed and combination
        5.6.2. Cisplatin and combination
        5.6.3. Carboplatin and combination
        5.6.4. Gemcitabine and combination
        5.6.5. Vinorelbine and combination
        5.6.6. Others combinations
   5.7. Market Size (US$ Mn) Forecast By Drug Class, 2017–2025
        5.7.1. Premetrexed and combination
        5.7.2. Cisplatin and combination
        5.7.3. Carboplatin and combination
        5.7.4. Gemcitabine and combination
        5.7.5. Vinorelbine and combination
        5.7.6. Others combinations
   5.8. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2012–2016
        5.8.1. Oral
        5.8.2. Parenteral
   5.9. Market Size (US$ Mn) Forecast By Route of Administration, 2017–2025
        5.9.1. Oral
        5.9.2. Parenteral
   5.10. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2012–2016
        5.10.1. Hospital Pharmacies
        5.10.2. Retail Pharmacies
        5.10.3. Oncology Centers
   5.11. Market Size (US$ Mn) Forecast By Distribution Channel, 2017–2025
        5.11.1. Hospital Pharmacies
        5.11.2. Retail Pharmacies
        5.11.3. Oncology Centers
   5.12. Drivers and Restraints: Impact Analysis
   5.13. Market Attractiveness Analysis
        5.13.1. By Country
        5.13.2. By Drug Class
        5.13.3. By Route of Administration
        5.13.4. By Distribution Channel

6. Europe Malignant Mesothelioma Market Analysis 2012–2016 and Forecast 2017–2025
   6.1. Introduction
   6.2. Key Regulations
   6.3. Regional Market Dynamics
        6.3.1. Drivers
        6.3.2. Restraints
   6.4. Historical Market Size (US$ Mn) Analysis By Country, 2012–2016
        6.4.1. Germany
        6.4.2. U.K.
        6.4.3. France
        6.4.4. Italy
        6.4.5. Spain
        6.4.6. Russia
        6.4.7. Rest of Europe
   6.5. Market Size (US$ Mn) Forecast By Country, 2017–2025
        6.5.1. Germany
        6.5.2. U.K.
        6.5.3. France
        6.5.4. Italy
        6.5.5. Spain
        6.5.6. Russia
        6.5.7. Rest of Europe
   6.6. Historical Market Size (US$ Mn) Analysis By Drug Class, 2012–2016
        6.6.1. Premetrexed and combination
        6.6.2. Cisplatin and combination
        6.6.3. Carboplatin and combination
        6.6.4. Gemcitabine and combination
        6.6.5. Vinorelbine and combination
        6.6.6. Others combinations
   6.7. Market Size (US$ Mn) Forecast By Drug Class, 2017–2025
        6.7.1. Premetrexed and combination
        6.7.2. Cisplatin and combination
        6.7.3. Carboplatin and combination
        6.7.4. Gemcitabine and combination
        6.7.5. Vinorelbine and combination
        6.7.6. Others combinations
   6.8. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2012–2016
        6.8.1. Oral
        6.8.2. Parenteral
   6.9. Market Size (US$ Mn) Forecast By Route of Administration, 2017–2025
        6.9.1. Oral
        6.9.2. Parenteral
   6.10. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2012–2016
        6.10.1. Hospital Pharmacies
        6.10.2. Retail Pharmacies
        6.10.3. Oncology Centers
   6.11. Market Size (US$ Mn) Forecast By Distribution Channel, 2017–2025
        6.11.1. Hospital Pharmacies
        6.11.2. Retail Pharmacies
        6.11.3. Oncology Centers
   6.12. Drivers and Restraints: Impact Analysis
   6.13. Market Attractiveness Analysis
        6.13.1. By Country
        6.13.2. By Drug Class
        6.13.3. By Route of Administration
        6.13.4. By Distribution Channel

7. Asia Pacific Malignant Mesothelioma Market Analysis 2012–2016 and Forecast 2017–2025
   7.1. Introduction
   7.2. Key Regulations
   7.3. Regional Market Dynamics
        7.3.1. Drivers
        7.3.2. Restraints
   7.4. Historical Market Size (US$ Mn) Analysis By Country, 2012–2016
        7.4.1. China
        7.4.2. Japan
        7.4.3. India
        7.4.4. ASEAN
        7.4.5. Australia and New Zealand
        7.4.6. Rest of Asia Pacific
   7.5. Market Size (US$ Mn) Forecast By Country, 2017–2025
        7.5.1. China
        7.5.2. Japan
        7.5.3. India
        7.5.4. ASEAN
        7.5.5. Australia and New Zealand
        7.5.6. Rest of Asia Pacific
   7.6. Historical Market Size (US$ Mn) Analysis By Drug Class, 2012–2016
        7.6.1. Premetrexed and combination
        7.6.2. Cisplatin and combination
        7.6.3. Carboplatin and combination
        7.6.4. Gemcitabine and combination
        7.6.5. Vinorelbine and combination
        7.6.6. Others combinations
   7.7. Market Size (US$ Mn) Forecast By Drug Class, 2017–2025
        7.7.1. Premetrexed and combination
        7.7.2. Cisplatin and combination
        7.7.3. Carboplatin and combination
        7.7.4. Gemcitabine and combination
        7.7.5. Vinorelbine and combination
        7.7.6. Others combinations
   7.8. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2012–2016
        7.8.1. Oral
        7.8.2. Parenteral
   7.9. Market Size (US$ Mn) Forecast By Route of Administration, 2017–2025
        7.9.1. Oral
        7.9.2. Parenteral
   7.10. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2012–2016
        7.10.1. Hospital Pharmacies
        7.10.2. Retail Pharmacies
        7.10.3. Oncology Centers
   7.11. Market Size (US$ Mn) Forecast By Distribution Channel, 2017–2025
        7.11.1. Hospital Pharmacies
        7.11.2. Retail Pharmacies
        7.11.3. Oncology Centers
   7.12. Drivers and Restraints: Impact Analysis
   7.13. Market Attractiveness Analysis
        7.13.1. By Country
        7.13.2. By Drug Class
        7.13.3. By Route of Administration
        7.13.4. By Distribution Channel

8. Middle East & Africa Malignant Mesothelioma Market Analysis 2012–2016 and Forecast 2017–2025
   8.1. Introduction
   8.2. Key Regulations
   8.3. Regional Market Dynamics
        8.3.1. Drivers
        8.3.2. Restraints
   8.4. Historical Market Size (US$ Mn) Analysis By Country, 2012–2016
        8.4.1. GCC Countries
        8.4.2. South Africa
        8.4.3. North Africa
        8.4.4. Rest of MEA
   8.5. Market Size (US$ Mn) Forecast By Country, 2017–2025
        8.5.1. GCC Countries
        8.5.2. South Africa
        8.5.3. North Africa
        8.5.4. Rest of MEA
   8.6. Historical Market Size (US$ Mn) Analysis By Drug Class, 2012–2016
        8.6.1. Premetrexed and combination
        8.6.2. Cisplatin and combination
        8.6.3. Carboplatin and combination
        8.6.4. Gemcitabine and combination
        8.6.5. Vinorelbine and combination
        8.6.6. Others combinations
   8.7. Market Size (US$ Mn) Forecast By Drug Class, 2017–2025
        8.7.1. Premetrexed and combination
        8.7.2. Cisplatin and combination
        8.7.3. Carboplatin and combination
        8.7.4. Gemcitabine and combination
        8.7.5. Vinorelbine and combination
        8.7.6. Others combinations
   8.8. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2012–2016
        8.8.1. Oral
        8.8.2. Parenteral
   8.9. Market Size (US$ Mn) Forecast By Route of Administration, 2017–2025
        8.9.1. Oral
        8.9.2. Parenteral
   8.10. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2012–2016
        8.10.1. Hospital Pharmacies
        8.10.2. Retail Pharmacies
        8.10.3. Oncology Centers
   8.11. Market Size (US$ Mn) Forecast By Distribution Channel, 2017–2025
        8.11.1. Hospital Pharmacies
        8.11.2. Retail Pharmacies
        8.11.3. Oncology Centers
   8.12. Drivers and Restraints: Impact Analysis
   8.13. Market Attractiveness Analysis
        8.13.1. By Country
        8.13.2. By Drug Class
        8.13.3. By Route of Administration
        8.13.4. By Distribution Channel

9. Competition Landscape
   9.1. Competition Dashboard
   9.2. Company Profiles (Details – Overview, Financials, Strategy, SWOT, Recent Developments)
        9.2.1. AstraZeneca Plc.
        9.2.2. Bristol-Myers Squibb Company
        9.2.3. F. Hoffmann-La Roche Ltd.
        9.2.4. Merck & Co., Inc.
        9.2.5. Novartis AG
        9.2.6. Pfizer Inc.
        9.2.7. Sanofi
        9.2.8. Eli Lilly and Company
        9.2.9. Teva Pharmaceuticals
        9.2.10. Boehringer Ingelheim GmbH
        9.2.11. Mylan N.V.
        9.2.12. Fresenius Kabi AG
        9.2.13. Sun Pharmaceuticals Industries Ltd
        9.2.14. Corden Pharma International GmbH
        9.2.15. Concordia International Corp
        9.2.16. Kyowa Hakko Kirin Co Ltd.
        9.2.17. Polaris Pharmaceuticals, Inc.
        9.2.18. MolMed SpA
        9.2.19. Ono Pharmaceutical Co. Ltd
        9.2.20. Nichi-Iko Pharmaceutical Co., Ltd

10. Global Malignant Mesothelioma Market Analysis 2012–2016 and Forecast 2017–2025, By Region
   10.1. Historical Market Size (US$ Mn) Analysis By Region, 2012–2016
        10.1.1. North America
        10.1.2. Latin America
        10.1.3. Europe
        10.1.4. Asia Pacific
        10.1.5. Middle East & Africa
   10.2. Market Size (US$ Mn) By Region, 2017–2025
        10.2.1. North America
        10.2.2. Latin America
        10.2.3. Europe
        10.2.4. Asia Pacific
        10.2.5. Middle East & Africa
   10.3. Market Attractiveness Analysis By Region

11. Global Malignant Mesothelioma Market Analysis 2012–2016 and Forecast 2017–2025, By Drug Class
   11.1. Historical Market Size (US$ Mn) Analysis By Drug Class, 2012–2016
        11.1.1. Premetrexed and combination
        11.1.2. Cisplatin and combination
        11.1.3. Carboplatin and combination
        11.1.4. Gemcitabine and combination
        11.1.5. Vinorelbine and combination
        11.1.6. Others combinations
   11.2. Market Size (US$ Mn) and Forecast By Drug Class, 2017–2025
        11.2.1. Premetrexed and combination
        11.2.2. Cisplatin and combination
        11.2.3. Carboplatin and combination
        11.2.4. Gemcitabine and combination
        11.2.5. Vinorelbine and combination
        11.2.6. Others combinations
   11.3. Market Attractiveness Analysis By Drug Class

12. Global Malignant Mesothelioma Market Analysis 2012–2016 and Forecast 2017–2025, By Route of Administration
   12.1. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2012–2016
        12.1.1. Oral
        12.1.2. Parenteral
   12.2. Market Size (US$ Mn) Forecast By Route of Administration, 2017–2025
        12.2.1. Oral
        12.2.2. Parenteral
   12.3. Market Attractiveness Analysis By Route of Administration

13. Global Malignant Mesothelioma Market Analysis 2012–2016 and Forecast 2017–2025, By Distribution Channel
   13.1. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2012–2016
        13.1.1. Hospital Pharmacies
        13.1.2. Retail Pharmacies
        13.1.3. Oncology Centers
   13.2. Market Size (US$ Mn) By Distribution Channel, 2017–2025
        13.2.1. Hospital Pharmacies
        13.2.2. Retail Pharmacies
        13.2.3. Oncology Centers
   13.3. Market Attractiveness Analysis By Distribution Channel

14. Global Malignant Mesothelioma Market Analysis 2012–2016 and Forecast 2017–2025
   14.1. Market Size and Y-o-Y Growth

Custom Market Research Services

MRRSE offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Get A Free Custom Research Quote